DYN

Dyne Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 4/10
  • Value↑ 5/10
Dyne Therapeutics sales and earnings growth
DYN Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 11.14%
  • FCF Y/Y↓ -43.14%
Dyne Therapeutics gross and profit margin trends
DYN Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -177.40%
Dyne Therapeutics net debt vs free cash flow
DYN Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -42.5

Dyne Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks